Search results for: Oncology
Filter search results
OHE at HTAi 2017: Meet the Team
13 June 2017
…ten potential elements of value, four familiar ones and six new. These are highlighted in a recent OHE-AIM report. Presentation: Extrapolation From Progression Free Survival To Overall Survival In Oncology…
OHE at HTAi Rome
12 July 2017
…Overall Survival (OS) in Oncology. This presentation looked at the methods used to extrapolate PFS to OS in the field of oncology, as well as at the key limitations, weaknesses…
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
Share this: Download publication Henry Fong Priscila Radu Nadine Henderson Martina Garau Lotte Steuten Key messages Tumour-agnostic (TA) therapies disrupt conventional oncology paradigms by targeting molecular alterations rather than tumour…
Is the revised Congressional Budget Office model of new drug development fit for purpose?
6 May 2026
…of existing drugs, which represents a critical source of treatment advances for patients, particularly in areas such as oncology and rare disease. Considering the dominance of multi-indication drugs in some…
Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase
3 October 2019
…Devlin, N. (2018). Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology. OHE Consulting Report. RePEc. Towse, A. and Garrison, L., 2017. Value assessment…
The Inflation Reduction Act: Price negotiation underway for the first 10 drugs
29 November 2023
…the drugs treat more than one condition. Two of the drugs are used to treat autoimmune disorders such as psoriasis, rheumatoid arthritis and Crohn’s disease. There is only one oncology…
Combination Therapies: A Step Forward to the Value Attribution Problem
4 January 2023
…and more unintended consequences in the long term. Why We Need a New Outcomes-Based Value Attribution Framework for Combination Regimens in Oncology, co-authored by Adrian Towse (OHE), Dr Mickael Lothgren…
Unlocking the Value of Combination Therapies
9 July 2024
…CTs are increasingly being used in oncology. Key takeaways The current approach to attributing value to therapies used in combination is the incremental value (IV) approach. However, this method faces…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…medicine (a “follow-on” indication). This represents a hugely important and growing route to new treatment options for many patients, particularly in oncology, immunology, and rare diseases, among others. Adopting policies…